低疫苗接种率人群中人乳头瘤病毒疫苗对宫颈癌前病变的影响
本研究基于2008—2018年田纳西州医疗补助参保女性数据,采用经验证的理赔模型识别宫颈上皮内瘤变2或3级及原位腺癌事件,用Joinpoint分析年龄别发病率趋势。结果显示18—29岁女性高级别宫颈病变发病率显著下降,30—39岁稳定;在筛查女性中18—29岁也显著下降。
要点
- 18—20岁女性高级别宫颈病变发病率年均下降31.9%(95%CI -38.6, -24.6)。
- 筛查女性中18—20岁发病率年均下降20.3%(95%CI -25.3, -15.0)。
- 30—34岁和35—39岁女性2008—2018年趋势稳定。
核心结论
- 结果显示,最可能受益于人乳头瘤病毒疫苗的年龄段高级别宫颈病变发病率下降。
- 年轻筛查女性中的下降提示存在筛查减少以外的原因。
- 在田纳西州等低疫苗接种覆盖率人群中观察到疫苗影响的证据令人鼓舞。
研究设计与样本
- 研究使用经验证的基于理赔的模型识别 Incident 宫颈上皮内瘤变2或3级或原位腺癌事件。
- 数据来源为2008—2018年田纳西州医疗补助账单数据,计算年龄组别年发病率。
- 采用Joinpoint确定显著趋势,分析于2020年进行。
主要发现
- 2008—2018年,18—20岁女性高级别宫颈病变发病率显著下降,年均百分比变化为-31.9(95%CI -38.6, -24.6)。
- 21—24岁女性年均百分比变化为-12.9(95%CI -22.3, -2.4),25—29岁女性为-6.4(95%CI -8.1, -4.6)。
- 在筛查女性中,18—20岁年均百分比变化为-20.3(95%CI -25.3, -15.0),21—24岁为-10.2(95%CI -12.6, -7.8),25—29岁为-2.6(95%CI -3.9, -1.2)。
- 30—34岁和35—39岁女性2008—2018年趋势稳定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Demonstrating human papillomavirus vaccine impact is critical for informing guidelines to increase vaccination and decrease human papillomavirus‒related outcomes, particularly in states with suboptimal vaccination coverage, such as Tennessee. This study examines the trends in high-grade cervical lesion incidence among Tennessee Medicaid-enrolled women aged 18-39 years and the subset of women who were screened for cervical cancer. METHODS: Using a validated claims-based model to identify incident cervical intraepithelial neoplasia Grades 2 or 3 or adenocarcinoma in situ events, annual age group‒specific incidence rates from Tennessee Medicaid billing data, 2008-2018, were calculated. Significant trends were determined by Joinpoint. Analyses were conducted in 2020. RESULTS: From 2008 to 2018, high-grade cervical lesion incidence significantly declined in women aged 18-20 years (average annual percentage change= -31.9, 95% CI= -38.6, -24.6), 21-24 years (average annual percentage change= -12.9, 95% CI= -22.3, -2.4), and 25-29 years (average annual percentage change= -6.4, 95% CI= -8.1, -4.6). Among screened women, rates significantly declined for ages 18-20 years (average annual percentage change= -20.3, 95% CI= -25.3, -15.0), 21-24 years (average annual percentage change= -10.2, 95% CI= -12.6, -7.8), and 25-29 years (average annual percentage change= -2.6, 95% CI= -3.9, -1.2). Trends from 2008 to 2018 were stable for older age groups (30-34 and 35-39 years). CONCLUSIONS: Results show reductions in high-grade cervical lesion incidence among ages most likely to have benefited from the human papillomavirus vaccine. Declines among young, screened women suggest causes other than reduction in screening. Evidence of vaccine impact in populations with low-vaccination coverage, such as Tennessee, is promising.
引用
- Shing JZ, Griffin MR, Chang RS, et al. Human Papillomavirus Vaccine Impact on Cervical Precancers in a Low-Vaccination Population. Am J Prev Med. 2021. PMID: 34756753. doi:10.1016/j.amepre.2021.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。